Atrophic vaginitis, also termed vulvovaginal atrophy, is a benign, estrogen‑deficiency–related condition characterized by thinning, drying, and inflammation of the vaginal epithelium and adjacent vulvar tissues. It most commonly occurs in postmenopausal women but can also be observed in premenopausal individuals with hypoestrogenic states such as premature ovarian insufficiency, certain surgical menopause scenarios (e.g., bilateral oophorectomy), or chronic use of anti‑estrogenic medications (e.g., aromatase inhibitors, selective estrogen receptor modulators).
Pathophysiology
The condition results from reduced circulating estrogen, which normally stimulates proliferation and glycogen deposition in the vaginal mucosa. Decreased estrogen leads to:
- Atrophy of the stratified squamous epithelium, causing a thinner, less robust lining.
- Reduction in vaginal secretions, contributing to decreased lubrication and increased mucosal fragility.
- Alterations in the vaginal microbiome, often with a decline in lactobacilli and a rise in pH, predisposing to irritation and infection.
Clinical presentation
Patients typically report one or more of the following symptoms:
- Vaginal dryness and burning sensation.
- Dyspareunia (painful sexual intercourse).
- Vaginal itching, irritation, or a feeling of “tightness.”
- Urinary symptoms such as frequency, urgency, or recurrent urinary tract infections, secondary to adjacent urethral irritation.
- Occasionally, mild spotting or post‑coital bleeding due to friable mucosa.
Diagnosis
Diagnosis is primarily clinical, based on symptomatology and a physical examination revealing:
- Pale, thin vaginal walls with loss of rugae.
- Reduced vaginal elasticity and decreased moisture.
- A higher vaginal pH (normally ≤4.5).
Adjunctive investigations may include a vaginal pH test, a swab for microbiological assessment if infection is suspected, or a pelvic ultrasound to exclude other pathologies.
Management
Therapeutic strategies aim to restore estrogenic stimulation and alleviate symptoms:
| Treatment modality | Typical use | Comments |
|---|---|---|
| Local estrogen therapy (e.g., estradiol or conjugated estrogen creams, tablets, or vaginal rings) | First‑line for most symptomatic women | Low systemic absorption; effective in reversing mucosal atrophy. |
| Systemic hormone therapy (oral, transdermal) | Considered for women with broader menopausal symptoms | Higher systemic exposure; contraindicated in certain high‑risk groups. |
| Non‑hormonal moisturizers and lubricants | Adjunct or alternative for women contraindicated for estrogen | Provide symptomatic relief but do not reverse atrophy. |
| Selective estrogen receptor modulators (SERMs) or tibolone | Alternative hormonal options in specific cases | Variable efficacy; require individualized risk‑benefit assessment. |
| Pelvic floor physical therapy | May improve sexual function and comfort | Often used alongside pharmacologic treatment. |
Epidemiology
Atrophic vaginitis affects an estimated 20–30 % of postmenopausal women, with prevalence increasing with age and duration since menopause. The condition is under‑reported, as many women consider symptoms a normal aspect of aging and may not seek medical care.
Prognosis
With appropriate therapy, most patients experience significant symptom improvement and restoration of vaginal health. Untreated atrophy can predispose to recurrent urinary tract infections, genital discomfort, and reduced sexual satisfaction, but it is not a precancerous condition.
References
(Encyclopedic entries typically cite peer‑reviewed medical textbooks and guidelines; specific citations are omitted here per instruction.)